Atlas Trials

Trilaciclib in Preventing Hematopoietic Suppression in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Clinical trial NCT06714266 · NOT_YET_RECRUITING

Trial details

NCT number
NCT06714266
Sponsor
Shandong Cancer Hospital and Institute
Status
NOT_YET_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Head and Neck Squamous Cell Carcinoma (HNSCC)
Start date
2024-12-15
Primary completion
2026-08-31
Enrollment
30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.